<DOC>
	<DOC>NCT01171417</DOC>
	<brief_summary>For patients receiving Faslodex 500 mg, to compare the effectiveness in terms of Time to Progression (TTP) as a function of the line of treatment (i.e. 1st vs. 2nd vs. 3rd line). For all patients, to collect and explore real-life data on the epidemiology and management of Pseudomyxoma Peritonea (PMP) patients with HR+ advanced breast cancer (ABC) treated with Faslodex 500 mg or exemestane.</brief_summary>
	<brief_title>A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Signed written informed consent Female postmenopausal patient (or patient postovariectomy) and age ≥18 years Postmenopause ist defined as Age ≥ 60 years and natural menopause with menses &gt; 1year ago or FSH and E2 levels in the postmenopausal range or Patients who had bilateral ovariectomy (NCCN V.I. 2009) Histologically confirmed ER+ locally advanced or metastatic breast cancer Not eligible for curative therapy Prior treatment with tamoxifen Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI Patient is able to read and understand German Known hypersensitivity to Faslodex or Exemestane or any compounds of the drugs Prior treatment with Faslodex 500 mg or Faslodex 250 mg* for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment. Prior treatment with Exemestane for patients who receive treatment with Exemestane within this observational study Acutely life threatening disease Treatment with Faslodex 250 mg/month (previously approved dose) Prior palliative chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Fulvestrant</keyword>
	<keyword>Exemestane</keyword>
	<keyword>postmenopausal patients</keyword>
	<keyword>advanced HR+ breast cancer</keyword>
	<keyword>Hormone Receptor positive</keyword>
	<keyword>advanced breast cancer</keyword>
</DOC>